Objectives The purpose of this study is to evaluate the effects of Gamitaeeumjowi-tang on the weight changes and adverse events in overweight or obese prediatric-adolescents. Methods A multicenter and retrospective chart review was performed on 425 overweight and obese pediatric-adolescents who took Gamitaeeumjowi-tang from May 2022 to November 2023. Outcomes were measured in terms of total weight loss and weight loss percentage, as well as the percentage of patients who lost at least 5% and 10% of their baseline weight. Patient-reported adverse events were collected and analyzed for frequency of occurrence, and whether they were serious enough to require discontinuation. Results A total of 47 patients were included, with a mean (±standard deviation) age of 15.00±1.90 years, weight of 85.59 ±19.24 kg, and body mass index of 30.81±4.98 kg/m2; 74.47% were female. The mean (±standard deviation) weight loss was 8.84±4.93 kg and the mean weight loss rate was 10.23±4.28%. The percentage of patients who lost at least 5% and 10% of their baseline weight was 95.74% and 54.20% respectively. No serious adverse events were reported. Conclusions Gamitaeeumjowi-tang was shown to help pediatric-adolescents who were overweight or obese to lose weight, and no serious adverse events were associated with discontinuation of the medication. Further well-designed clinical studies are recommended.
서론
대상 및 방법
연구결과
고찰
결론
Conflict of Interest
References
(0)
(0)